Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327:400 (16 August), doi:10.1136/bmj.327.7411.400
How HRT studies have got drug firms rallying the troops
| The first 150 words of the full text of this article appear below. |
So the headlines have dealt another blow to the image of hormone replacement therapy (HRT). Will the drug companies be able to revive the fortunes of one of their most lucrative products? Will the big guns of the pharmaceutical industry be blazing, eager to counteract the latest volley of bad publicity? Or will the industry construct its defences more subtly?
Certainly, if the history of HRT promotion is anything to go by, the pharmaceutical public relations machine will be doing all it can to limit the fallout from studies published last week in the
New England Journal of Medicine
(2003;349: 523-34)
-->-->
Jocalyn Clark, editorial registrar
BMJ jclark@bmj.com
Read all Rapid Responses